Stay updated with breaking news from Patrick Mcgann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Two rival gene-based treatments developed by three biotech firms with headquarters, or most of their operations, in Mass. could be approved late this year or early in 2024.
Sickle cell disease was long considered a pediatric illness because it took so many children's lives. Health interventions have made it possible for people with sickle cell in the U.S. to live well into adulthood. But the transition out of pediatric care comes with many challenges.
Sickle cell disease was long considered a pediatric illness because it took so many children's lives. Health interventions have made it possible for people with sickle cell in the U.S. to live well into adulthood. But the transition out of pediatric care comes with many challenges.
Sickle cell disease was long considered a pediatric illness because it took so many children's lives. Health interventions have made it possible for people with sickle cell in the U.S. to live well into adulthood. But the transition out of pediatric care comes with many challenges.
Sickle cell disease was long considered a pediatric illness because it took so many children's lives. Health interventions have made it possible for people with sickle cell in the U.S. to live well into adulthood. But the transition out of pediatric care comes with many challenges.